Lilly Foundayo is predicted to cut diabetes risk by 57% in late-stage study

Phase 3positiveLilly FoundayoPositive

AI Analysis

Summary

Lilly's Foundayo demonstrated a 57% diabetes risk reduction in a late-stage clinical study, representing a positive Phase 3 trial outcome for the diabetes indication.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

predicted to cut diabetes risk by 57% in late-stage study

Importance:7/10

Sentiment:

0.75

Phase 3diabeteslate-stage studypositive efficacy

Related Companies

$LLY

Read the original article

Published by Seeking Alpha Healthcare on October 1, 2026 11:37 AM

Read Original